Idiopathic pulmonary fibrosis: integration of modern diagnostic and therapeutic algorithms
A. A. Filippova,
N. V. Lareva,
E. V. Luzina,
А. А. Zhilina,
S. М. Tsvinger,
Е. B. Zhigzhitova,
Z. М. Zhigula,
Е. А. Tomina,
Е. S. Zaguzina https://doi.org/10.52485/19986173_2026_1_189
Abstract
Idiopathic pulmonary fibrosis (IPF) is a severe disease with an unfavorable prognosis, requiring a comprehensive, multidisciplinary approach to diagnosis and treatment.
Its clinical presentation is dominated by nonspecific symptoms, primarily progressive dyspnea and cough, which clinicians may attribute to similar conditions (COPD, CHF, and others), thereby delaying verification of the diagnosis. Early diagnosis and the timely initiation of targeted therapy are crucial for improving patient outcomes.
Antifibrotic medications (pirfenidone and nintedanib) are essential in IPF treatment, slowing pulmonary function decline and improving survival, particularly when initiated early.
They exhibit comparable safety and efficacy profiles.
Supporting agencies: The study had no financial support
About the Authors
A. A. Filippova
Chita State Medical Academy
Russian Federation
Russian Federation
Candidate of Medical Sciences, Assistant
Faculty of Additional Professional Education; Department of Therapy
672000; 39a Gorky St.; Chita
N. V. Lareva
Chita State Medical Academy; Trans-Baikal Regional Branch of the Russian Scientific Medical Society of Internal Medicine
Russian Federation
Russian Federation
Doctor of Medical Sciences, Professor, Acting Rector, Vice-rector for Research and International Affairs, Head of the Department, Chairman of the Branch
Faculty of Additional Professional Education; Department of Therapy
672000; 39a Gorky St.; Chita
E. V. Luzina
Chita State Medical Academy; Trans-Baikal Scientific Society of Gastroenterologists
Russian Federation
Russian Federation
Candidate of Medical Sciences, Associate Professor, Associate Professor of the Department, Chairman of the Society
Faculty of Additional Professional Education; Department of Therapy
672000; 39a Gorky St.; Chita
А. А. Zhilina
Chita State Medical Academy
Russian Federation
Russian Federation
Doctor of Medical Sciences, Vice-Rector for Academic Affairs, Educational Activities and Youth Policy, Professor
Faculty of Additional Professional Education; Department of Therapy
672000; 39a Gorky St.; Chita
S. М. Tsvinger
Chita State Medical Academy
Russian Federation
Russian Federation
Doctor of Medical Sciences, Associate Professor, Dean
Faculty of Additional Professional Education; Department of Therapy; Faculty of General Medicine
672000; 39a Gorky St.; Chita
Author ID Scopus 57194773369
Е. B. Zhigzhitova
Chita State Medical Academy
Russian Federation
Russian Federation
Candidate of Medical Sciences, Assistant
Faculty of Additional Professional Education; Department of Therapy
672000; 39a Gorky St.; Chita
Z. М. Zhigula
Chita State Medical Academy
Russian Federation
Russian Federation
Candidate of Medical Sciences, Associate Professor
Faculty of Additional Professional Education; Department of Therapy
672000; 39a Gorky St.; Chita
Author ID РИНЦ 636891
Е. А. Tomina
Chita State Medical Academy
Russian Federation
Russian Federation
Candidate of Medical Sciences, Associate Professor
Faculty of Additional Professional Education; Department of Therapy
672000; 39a Gorky St.; Chita
Е. S. Zaguzina
State Autonomous Health Institution «Transbaikal Regional Clinical Hospital»
Russian Federation
Russian Federation
Head of the Department
Pulmonology Department
672038; 7 Kokhansky St.; Chita
References
1. Avdeev S.N., Aisanov Z.R., Belevskiy A.S. et alt. Federal clinical guidelines on diagnosis and treatment of idiopathic pulmonary fibrosis. PULMONOLOGIYA. 2022. 32 (3): 473–495. (In Russ.) DOI: 10.18093/0869-0189-2022-32-3-473-495.
2. Chuchalin A. G. Respiratory medicine: a manual. Moscow. PulmoMedia. 2025. (In Russian). DOI: 10.18093/978-5-6048754-7-6-2024-3.
3. Trushenko N.V., Levina Y.A., Lavginova B.B., Suvorova O.А., Avdeev S.N. Prospects of pirfenidone use in idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. Meditsinskiy sovet = Medical Council. 2025. (9): 107–117. (In Russ.) DOI: 10.21518/ms2025-201.
4. Ignatova G.L., Blinova E.V., Belsner M.S., Korotkaia M.A. Idiopathic pulmonary fibrosis: a clinical case of long-term follow-up. Consilium Medicum. 2022; 24 (9): 640–644. DOI: 10.26442/20751753.2022.9.201962.
5. Ivashkin V.T., Trukhmanov A.S., Maev I.V. et alt. Diagnosis and Treatment of Gastroesophageal Reflux Disease (Clinical Guidelines of the Russian Gastroenterological Association, Russian Scientific Medical Society of Internal Medicine, Russian Society for the Prevention of Noncommunicable Diseases, Scientific Сommunity for Human Microbiome Research). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2024; 34 (5): 111–135. DOI: 10.22416/1382-4376-2024-34-5-111-135.
6. Podolanczuk A.J., Noth I., Raghu G. Idiopathic pulmonary fibrosis: prime time for a precision-based approach to treatment with N-acetylcysteine. Eur Respir J. 2021. 57 (1):2003551. DOI: 10.1183/13993003.03551-2020.
7. Zhang Y., Qi C., Wei Q., Li Y., Tian P. Pathogenesis and current status of the treatment of lung cancer associated with idiopathic pulmonary fibrosis. Respir Res. 2025. 26 (1): 230. DOI: 10.1186/s12931-025-03294-7.
8. Raghu G., Remy-Jardin M., Richeldi L. et alt. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022. 205 (9): e18-e47. DOI: 10.1164/rccm.202202-0399ST.
9. Iftikhar S., Alhaddad S.F., Paulsingh C.N. et alt. The Role of Proton Pump Inhibitors in the Realm of Idiopathic Pulmonary Fibrosis and its Associated Comorbidities : A Systematic Review. Cureus. 2024. 16 (3):e55980. DOI: 10.7759/cureus.55980.
10. Florian J., Watte G., Teixeira P.J.Z. Pulmonary rehabilitation improves survival in patients with idiopathic pulmonary fibrosis undergoing lung transplantation. Sci Rep. 2019 Jun. 27; 9 (1): 9347. DOI: 10.1038/s41598-019-45828-2.
11. Aktan R., Tertemiz K.C., Yiğit S. et alt. Effects of home-based telerehabilitation-assisted inspiratory muscle training in patients with idiopathic pulmonary fibrosis: A randomized controlled trial. Respirology. 2024. 29 (12): 1077–1084. DOI: 10.1111/resp.14810.
Review
For citations:
Filippova A.A., Lareva N.V., Luzina E.V., Zhilina А.А., Tsvinger S.М., Zhigzhitova Е.B., Zhigula Z.М., Tomina Е.А., Zaguzina Е.S. Idiopathic pulmonary fibrosis: integration of modern diagnostic and therapeutic algorithms. Transbaikalian Medical Bulletin. 2026;(1):189-199. (In Russ.) https://doi.org/10.52485/19986173_2026_1_189
Views:
149
JATS XML
Email this article 